LSS rs2254524 Increases the Risk of Hypertension in Children and Adolescents with Obesity

Childhood obesity and its related comorbidities have become major health issues over the last century. Among these comorbidities, cardiovascular diseases, especially hypertension, are the most significant. Recently, a polymorphism affecting the activity of lanosterol synthase has been associated with an increased risk of hypertension in adolescents. In this study, we aimed to investigate the effect of LSS rs2254524 polymorphism on blood pressure in children and adolescents with obesity. We enrolled 828 obese children aged 6-17 years. Subjects carrying the A allele showed higher rates of systolic and diastolic stage I hypertension and stage II hypertension. Carriers of the A allele showed a 2.4-fold (95% C.I. 1.5-4.7, p = 0.01) higher risk for stage II hypertension and a 1.9-fold higher risk for stage I hypertension (95% C.I. 1.4-2.6, p < 0.0001). The risk was independent of confounding factors. In conclusion, LSS rs2254524 worsens the cardiovascular health of children and adolescents with obesity, increasing their blood pressure.

Automated summary

This study aimed to investigate the effect of LSS rs2254524 polymorphism on blood pressure in obese children and adolescents. The study found that individuals carrying the A allele had a higher risk of developing stage I and stage II hypertension. This risk was independent of confounding factors. Therefore, LSS rs2254524 worsens cardiovascular health in obese children and adolescents by increasing blood pressure.